retatrutide peptide oral Retatrutide: The New Triple-Agonist Weight Loss Treatment Retatrutide for Weight Loss: TRIUMPH-1
Description
It has a 1.9% weighting in Tema's fund and a market cap of $8.5 billion
doi: 10.1038/s41423-025-01275-w
19,20 The mechanisms of SGLT2 inhibitors are multifactorial and related to a diuretic effect, improved myocardial and vascular metabolism leading to lower preload, reduced afterload, and improvements in cardiac structure and function
GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study
Phase 3 trials for obesity completed in August 2025
